E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020192 |
E.1.2 | Term | HIV-1 |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Main objectives:
Safety: Number of participants with Adverse Events as a measure of safety and tolerability
Tolerability: Number of participants with Adverse
Events as a measure of safety and tolerability
Pharmacokinetics: Measure the blood concentration of
ETR, ng/ml-1. Population PK parameters for ETR (AUC12h and C0h)
HIV Drug Resistance: Assess potential development of drug resistance to secondary outcomes
Immunological Assessment: Assessment of possible improvement of CD4 lymphocytes (immune system
cells) |
|
E.2.2 | Secondary objectives of the trial |
Secundary objectives:
Virologic suppression: viral load value HIV-1 RNA
copies/mL
Antiviral activity: CD4 & viral load value HIV-1 RNA
copies/mL
Virologic suppression: viral load value HIV-1 RNA
copies/mL |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
A substudy of TMC125IFD3002 to evaluate the pharmacokinetic profile of etravirine at steady-state, when coadministered with an individually optimized antiretroviral therapy other than darunavir/ritonavir. |
|
E.3 | Principal inclusion criteria |
Have not changed your drugs to treat HIV for 8 weeks and currently experiencing virologic failure, (viral load value ≥ 500 HIV 1 RNA copies /mL); or switching due to simplification of their regimen or due to adverse event or tolerability reasons, (viral load value <50 HIV 1 RNA copies /mL). You must have demonstrated sensitivity to ETR and to at least 1 ARV in the background regimen, based on the resistance test for subjects with a screening viral load ≥ 500 HIV-1 RNA copies/mL or based on historical ARV resistance testing or ARV treatment history for
those group of subjects entering the study with a plasma viral load < 50 HIV-1 RNA copies/mL. You must agree not to have unprotected sex while on the study. You must not have a currently active AIDS defining illness. You must not take any non-ARV investigational agents within 90 days prior to screening. You must not use of any drugs or other therapies that your doctors tell you are disallowed. Your doctor must check that your liver is functioning correctly. Any disease that in your study doctor's opinion, would compromise the subject's safety. |
|
E.4 | Principal exclusion criteria |
Any currently active illness or toxicity due to your HIV infection |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety: Number of participants with Adverse
Events as a measure of safety and tolerability
Tolerability: Number of participants with Adverse Events as a measure of safety and
tolerability
Pharmacokinetics: Measure the blood concentration of ETR, ng/ml-1. Population PK parameters for ETR (AUC12h and C0h)
HIV Drug Resistance: Assess potential development of drug resistance to secondary outcomes
Immunological Assessment: Assessment of possible improvement of CD4 lymphocytes (immune system
cells)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Virologic suppression: viral load value HIV-1 RNA copies/mL
Antiviral activity: CD4 & viral load value HIV-1 RNA copies/mL
Virologic suppression: viral load value HIV-1 RNA copies/mL |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 16 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
France |
Guatemala |
India |
Mexico |
Peru |
Poland |
Romania |
Russian Federation |
South Africa |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |